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Targeting mitotic chromosomes: a conserved
mechanism to ensure viral genome persistence
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Received
AcceptedViruses that maintain their genomes as extrachromosomal circular DNA molecules and establish infection
in actively dividing cells must ensure retention of their genomes within the nuclear envelope in order to
prevent genome loss. The loss of nuclear membrane integrity during mitosis dictates that paired host cell
chromosomes are captured and organized by the mitotic spindle apparatus before segregation to daughter
cells. This prevents inaccurate chromosomal segregation and loss of genetic material. A similar mechanism
may also exist for the nuclear retention of extrachromosomal viral genomes or episomes during mitosis,
particularly for genomes maintained at a low copy number in latent infections. It has been heavily debated
whether such a mechanism exists and to what extent this mechanism is conserved among diverse viruses.
Research over the last two decades has provided a wealth of information regarding the mechanisms by
which specific tumour viruses evade mitotic and DNA damage checkpoints. Here, we discuss the
similarities and differences in how specific viruses tether episomal genomes to host cell chromosomes
during mitosis to ensure long-term persistence.
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While the specific mechanism of genome segregation
during mitotic cellular division employed by each DNA
virus studied has subtle or sometimes major distinctions,
the overall theme of the way in which viruses have evolved
to ensure genome persistence in dividing cells remains
strikingly similar. Viral genomes are replicated along with
the cellular DNA and are attached to host cell chromo-
somes during cellular division. This ensures retention in the
nuclear envelope and in some cases may facilitate a roughly
even distribution of episomal DNA molecules to each
daughter cell (figure 1). To facilitate this mechanism of
genome tethering, each virus encodes a DNA-binding
protein, which specifically associates with repeated
sequences within the viral genome. The viral DNA-binding
protein then targets host cell proteins that themselves
associate with mitotic chromatin, thus tethering viral
genomes to the host cell DNA during mitotic segregation
(figure 2). This elegant mechanism appears to have evolved
to ensure viral persistence during low copy latent infections,
and thus provides a powerful and novel antiviral target. The
similarities and differences in the way in which different
DNA tumour viruses have developed their own segregation
mechanism will be discussed in this review.2. EPSTEIN–BARR VIRUS
Epstein–Barr virus (EBV) is a human g-herpesvirus
(genus lymphocryptovirus) that persists benignly in
approximately 90 per cent of individuals worldwide.
In developing countries, infection occurs in earlyr for correspondence (jlp10@st-andrews.ac.uk).
11 November 2008
19 December 2008 1535childhood and is generally asymptomatic. Owing to
better hygiene standards, infection is delayed until
early adolescence in developed countries where it can
result in infectious mononucleosis (Rickinson et al. 2000).
Persistent EBV infection is tightly linked to the develop-
ment of several human cancers including Burkitt’s
lymphoma, Hodgkin’s disease and nasopharyngeal carci-
noma (Crawford 2001). Although EBV potently trans-
forms cells in culture, it is known to persist in vivo not by
immortalizing infected B cells, but by establishing a true
latency in normal resting memory B cells (Thorley-
Lawson 2005).
During a latent infection, the EBV genome is episo-
mally maintained as a 165 kb double-stranded circular
DNA molecule, where nine latent proteins including five
EBV nuclear antigens (EBNA) and three latent membrane
proteins are expressed. These proteins are required to
stimulate proliferation of the host cell and maintain a
stable viral copy number within dividing cells (Thorley-
Lawson 2005). Replication of the viral genome is
stimulated once per cell cycle (Adams 1987) and requires
repeat sequences within the viral origin of replication
OriP and the viral EBNA1 protein (Lupton & Levine
1985; Reisman et al. 1985; Yates et al. 1985, 2000;
Middleton & Sugden 1992).OriP contains 20 high-affinity
18 bp EBNA1-binding sites within the family of repeats
(FR) element and four low-affinity binding sites within the
dyad symmetry (DS) element (Reisman et al. 1985).
Through its specific affinity for sequences within OriP,
EBNA1 is also essential for transcriptional control of viral
enhancers and promoters (Reisman & Sugden 1986;
Sugden & Warren 1989; Wysokenski & Yates 1989;
Altmann et al. 2006), and the retention of the viralThis journal is q 2009 The Royal Society
(b)
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Figure 1. Genome tethering during mitosis ensures nuclear retention and viral persistence. (a) In the absence of a tethering
mechanism, episomally maintained DNA molecules (red circles) are potentially partitioned unevenly and excluded from the
nuclear compartment upon completion of mitosis. This leads to a non-productive and transient viral infection. (b) A robust
tethering mechanism ensures that episomal DNA molecules are more evenly distributed between daughter cells and remain in
the nuclear compartment, thus ensuring genome maintenance in dividing cells and persistent viral infection.
Figure 2. Mechanism of viral genome tethering during
mitosis. To ensure persistence in dividing cells, many
episomally maintained DNA viruses tether genomes to host
cell chromosomes during mitosis. In general, a virally
encoded DNA-binding protein (red) associates with specific
sequences within the viral genome (circle) while simul-
taneously associating with chromatin (blue)-bound cellular
protein(s) (green). This intricate tethering mechanism
appears conserved among diverse viral types.
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Langle-Rouault et al. 1998).
The viral genome partitioning function of EBNA1 has
been directly attributed to its ability to associate with host
cell chromosomes during mitosis. EBNA1 localizes to
discrete foci during mitosis that colocalize with host cell
mitotic chromosomes (Grogan et al. 1983; Petti et al.
1990). Deletion studies have demonstrated that three
independent domains of EBNA1 are involved in mitotic
chromosome binding. Each of these domains are rich in
basic residues and it is suggested that these regions may
assist in chromosomal attachment via interaction with
histone H1 (Marechal et al. 1999). Further work has
shown that EBNA1 targets the cellular protein EBNA1
binding protein 2 (EBP2) to facilitate genome partitioning
(Wu et al. 2000; Kapoor et al. 2001; Kapoor & Frappier
2003). The interaction between EBNA1 and EBP2 was
originally identified in a yeast two-hybrid screen (Shire
et al. 1999), and the requirement of EBP2 for the
association of EBNA1 with chromosomes and EBNA1-
dependent segregation of FR-containing plasmids was
demonstrated using a reconstituted yeast system (Kapoor
et al. 2001; Kapoor & Frappier 2003). In addition,
EBNA1 and EBP2 have been shown to colocalize on
mitotic chromosomes in human cells and deletion of one
of the chromosome-binding sites identified by Marechal
et al. (1999) results in a loss of association of EBNA1 with
EBP2 (Wu et al. 2000). Interestingly, it has been
demonstrated that the association of human EBP2 with
chromosomes is regulated by the Aurora family kinase
member Aurora B (Kapoor et al. 2005). This suggests a
role for the mitotic checkpoint regulator Aurora B in the
partitioning of EBV genomes, although EBP2 itself is not
thought to be a direct target of Aurora kinase.
In contrast to the studies described above, it has been
suggested that EBNA1 associates directly with mitotic
chromosomes in human cells independently of its
association with EBP2 (Lindner & Sugden 2007). This
interaction is proposed to be via an AT-hook motif within
EBNA1 that binds to adenosine/thymidine (A/T)-
rich DNA sequences (Sears et al. 2004). Similar to the
EBP2-binding region within EBNA1, the two EBNA1Proc. R. Soc. B (2009)AT-hook motifs overlap with chromosomal binding
regions described by Marechal et al. (1999), and it has
been shown that the partitioning function of EBNA1
correlates with its AT-hook activity and not with EBP2
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DNA binding and dimerization domain of EBNA1 that lacks
the EBP2-binding region, with cellular proteins containing
AT-hook motifs, supports wild-type levels of viral plasmid
replication and partitioning (Altmann et al. 2006).
Mutant EBNA1 proteins that fail to activate transient
replication of OriP-containing plasmids are also defective
in genome tethering function (Kanda et al. 2001).
Therefore, it has been suggested that EBNA1 functions
to couple viral genome replication during S-phase to the
subsequent tethering of replicated genomes to chromo-
somes during mitosis. In support of this, it has been
demonstrated that replicated OriP-containing plasmids
are spatially colocalized as pairs on mitotic chromosomes
and that this positioning is essential for their non-random
partitioning (Kanda et al. 2007; Nanbo et al. 2007).
Nanbo et al. (2007) speculated that EBNA1 associates
with chromosomal DNA during G1 and that replication of
a subset of viral genomes is coincident with progression to
the S-phase. This results in an association of the newly
replicated EBV sister plasmids with the same or nearby
sites on each sister chromatid where the cellular cohesin
complex (Nasmyth 2005) may be required to hold the
tethered EBV plasmids together. This model proposes
that the replicated EBV sister plasmids are segregated to
daughter cells as the sister chromatids separate at
anaphase and offers an exciting twist to the specific
mechanism EBV uses to maintain low copy number
episomal genomes in latent and persistent viral infections.3. RHADINOVIRUS
(a) Kaposi’s sarcoma-associated herpesvirus
Similar to EBV, Kaposi’s sarcoma-associated herpesvirus
(KSHV; also known as human herpesvirus 8, HHV-8) is a
g-herpesvirus. KSHV belongs to the genus Rhadinovirus
and is the only member of the genus known to infect
humans. The incidence of KSHV infection is low in Asia,
northern Europe, Australia and the Americas (less than
5%) but higher in Mediterranean countries (4–35%) and
sub-Saharan Africa (20–70%) (Schulz et al. 2002). KSHV
infection is typically asymptomatic in immunocompetent
individuals. Nonetheless, KSHV is the causative agent of
primary effusion myeloma, Castleman’s disease and
Kaposi’s sarcoma (Moore & Chang 2001). Kaposi’s
sarcoma, which is characterized by pigmented sarcomas
of the skin, is often the presenting symptom of acquired
immune deficiency syndrome (AIDS). In fact, KSHV was
discovered by the analysis of DNA fragments from AIDS-
associated Kaposi’s sarcoma (Chang et al. 1994).
The KSHV genome comprises a long unique region
(140 kb) flanked by two terminal repeat (TR) regions,
which consist of tandem repeats of 803 bps long (Russo
et al. 1996). The number of repeated sequences varies
between strains ( Judde et al. 2000). During latent
infection, only a relatively short portion (11 kb) of the
viral episome is transcribed. These latent transcripts
encode six proteins; viral cyclin D, latency-associated
nuclear antigen 1 (LANA1/LANA), Kaposin A and B,
viral FAS ligand interleukin-1B-converting enzyme inhibi-
tory protein, and the viral homologue of interferon
regulatory factor 3 (LANA2); and 12 pre-miRNAs
(reviewed in Laurent et al. 2008). To date, 86 openProc. R. Soc. B (2009)reading frames (ORFs) have been identified and possibly
more exist as further splice variants are discovered.
LANA protein is present in nearly all infected cells, and
therefore, anti-LANA antibodies can be used as a marker
of infection (Rainbow et al. 1997; Laney et al. 2006).
LANA, encoded by ORF73, plays multiple roles in the
viral life cycle and thus is the most extensively studied
latent transcript. LANA is required for viral replication,
episome maintenance and regulation of latent gene
expression. It has been clearly demonstrated that LANA
promotes progression through the cell cycle by interacting
with p53, pRb and c-Myc pathways (Friborg et al. 1999;
Radkov et al. 2000; Liu et al. 2007). Similar to EBV
EBNA1 and the papillomavirus E2 protein (discussed
below), disruption or depletion of LANA results in
reduced episomal maintenance (Ye et al. 2004; Godfrey
et al. 2005).
LANA facilitates viral DNA replication via a specific
interaction of the C-terminal DNA-binding domain with
two sites within the TR: LANA-binding site 1 (LBS1) and
LANA-binding site 2 (LBS2) (Garber et al. 2002; Hu et al.
2002). Computational analysis shows that the C-terminus
is similar in structure to the EBV EBNA1 DNA-binding
domain (Grundhoff & Ganem 2003). In addition, the
LBS1/2 regions are similar in organization to the EBV DS
element and binding of LANA and EBNA1, respectively,
is required for DNA replication (Rawlins et al. 1985; Yates
et al. 1985; Polvino-Bodnar & Schaffer 1992; Garber et al.
2002; Hu et al. 2002; Lim et al. 2002; Hu & Renne 2005).
It has recently been shown that LANA binds to host cell
origin recognition complexes (ORCs) and may recruit
ORCs to sites of latent origins of replication (Stedman
et al. 2004; Verma et al. 2006).
Almost a decade ago, two independent research groups
suggested a role for LANA in the tethering of viral
episomes to host chromosomes during mitosis (Ballestas
et al. 1999; Cotter & Robertson 1999). As previously
mentioned, LANA binds to the TR via its C-terminus
(Ballestas & Kaye 2001; Cotter et al. 2001; Komatsu et al.
2004). The residues within the C-terminus, which are
required for TR DNA binding, have been mapped in some
detail, and correspond to those required for EBNA1 DNA
binding (Kelley-Clarke et al. 2007). The mechanism by
which LANA associates with chromosomes remains to be
elucidated. LANA has a punctate nuclear distribution in
the presence of the KSHV genome or TR-containing
plasmids but in the absence of TR DNA, LANA is
distributed diffusely in the nucleus (Ballestas et al. 1999;
Schwam et al. 2000). Although both the N- and C-termini
can bind to chromosomes, it seems that LANA is recruited
to TR DNA via binding of the C-terminal domain while
the N-terminus tethers episomes to chromosomes by
binding chromosome-associated proteins (Piolot et al.
2001; Barbera et al. 2006).
Several cellular proteins have been implicated in the
genome tethering mechanism of KSHV. Recruitment of
LANA to mouse chromosomes has been shown to require
methyl CpG-binding protein (MeCP2) and DEK
(Krithivas et al. 2002). However, a more recent study
illustrates that the LANA residues responsible for
chromosome binding interact with histones H2A and
H2B (Barbera et al. 2006). Perhaps MeCP2 and
DEK, with their associated chromatin-modifying
properties, facilitate LANA binding to nucleosomes
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the aforementioned proteins, LANA has also been shown
to interact with Brd4, Brd2/Ring3, Histone H1 and
nuclear mitotic apparatus protein (NuMA; Cotter &
Robertson 1999; Ottinger et al. 2006; You et al. 2006;
Si et al. 2008). In addition to the cellular proteins directly
targeted by LANA, it has been shown that the cellular
cohesin complex and the transcriptional insulator
CCCTC-binding factor (CTCF) associate with sequences
within the latency control region of KSHV genomes, and
that together these factors play a role in the control of
latent gene expression (Stedman et al. 2008). The authors
also speculate that, similar to the related EBV, KSHV
genomes may remain associated following replication and
that genomes are actively segregated like host cell
chromosomes by the regulation of cohesin association.
Interestingly, CTCF has also been shown to associate with
EBV episomes, although this is thought to be required for
the transcriptional regulation of viral genes by facilitating
chromatin domain organization, and not for genome
maintenance per se (Chau et al. 2006; Day et al. 2007). It
is clear that further research is required to dissect the
contribution of individual cellular proteins to the
maintenance of episomal KSHV genomes.
(b) Other ORF73-encoded proteins
Almost all g2-herpesviruses encode homologous proteins
from ORF73. The proteins vary greatly in length; KSHV
LANA is one of the longest (1162 amino acids) while
bovine herpesvirus 4 (BoHV-4) ORF73 is the shortest
(253 amino acids). The acidic internal repeat region is the
least conserved region and varies in length and in some
species is completely absent (murine g-herpesvirus 68
(MHV-68), rhesus rhadinovirus (RRV) and BoHV-4).
Conversely, the N- and C-terminal regions of proteins
translated from ORF73 are highly conserved (Burnside
et al. 2006; Taus et al. 2007). Similar to LANA,
herpesvirus saimiri (HVS) ORF73 inhibits p53 and pRb
function and it has been shown that the expression of
MHV-68 ORF73 results in decreased p53 stabilization
(Borah et al. 2004; Forrest et al. 2007).
There is some evidence to suggest that the genome
tethering function of proteins expressed from ORF73 is
also conserved. HVS ORF73 has been shown to tether the
viral genome to host chromosomes and facilitate episomal
maintenance by binding to TR DNA (Collins et al. 2002;
Verma & Robertson 2003; White et al. 2003). Furthermore,
the C-terminus of HVS ORF73 is required for nuclear
localization, a feature which is also characteristic of KSHV
LANA (Hall et al. 2000). There have been a limited
number of studies on MHV-68 ORF73; however, it has
been demonstrated that ORF73 is required to establish and
maintain latency (Fowler et al. 2003; Moorman et al.
2003). It has also been shown that LANA can regulate viral
latency by inhibiting the replication and transcription
activator protein (RTA), which is encoded by ORF50
and functions as a transcriptional activator of early and late
lytic genes (Lan et al. 2004). Similarly, HSV ORF73 blocks
RTA-mediated transactivation by direct inhibition of
ORF50 expression (Schafer et al. 2003). RRV ORF73
also represses RTA-mediated transactivation, although the
mechanism is unclear (DeWire & Damania 2005). This
provides evidence that both HVS- and RRV ORF73-
encoded proteins inhibit ORF50 function. FurtherProc. R. Soc. B (2009)evidence for conservation of the lytic switch mechanism is
demonstrated by the fact that KSHV RTA can reactivate
MHV-68 from latency (Rickabaugh et al. 2005).4. PAPILLOMAVIRUS
Papillomaviruses are a diverse group of small DNA viruses
that infect epithelial cells with numerous clinical out-
comes. There are approximately 120 viral types described
that infect mammals and birds with a high degree of
species specificity. Of these, approximately 100 human
papillomavirus (HPV) types have been defined, which
infect the basal cells of either mucosal or cutaneous
epithelia in a variety of biological niches (de Villiers et al.
2004). Once infection is established, papillomaviruses can
persist in infected individuals for long periods of time and
many types appear to have a latent life cycle where
viral DNA can be detected in areas of healthy skin
(Antonsson & Hansson 2002; Antonsson et al. 2003).
HPV infection commonly causes benign tumours (warts
and papillomas) but is often associated with malignant
progression including cervical, anogenital or oropharyn-
geal carcinomas. HPVs are subdivided into five genera
depending on the preferential site of infection and clinical
outcome. The two largest HPV genera are the alpha and
beta papillomaviruses and comprise 90 per cent of all
known HPV types. The association of specific HPV types
with carcinoma is used to further classify viral types. For
example, within the alpha or genital/mucosal papilloma-
virus group, HPV types 6 and 11 are classified as low-risk
and have little or no association with anogenital carcinoma
whereas infection at the same site with high-risk HPVs,
such as types 16 and 18, can result in malignant
progression. In support of this, it has been shown that
more than 99.7 per cent of cervical cancers contain high-
risk HPV DNA with approximately 50 per cent of these
containing HPV-16 DNA (Doorbar 2006).
All papillomaviruses contain an approximately 8000 bp
double-stranded circular DNA genome that encodes eight
or nine ORFs including six early ORFs (E1, E2, E4, E5,
E6 and E7) and two late ORFs (L1 and L2). Upon
infection of basal cells within the epidermis, the viral
genome is established as a stable episome and maintained
at a low copy number. Viral genomes are replicated along
with the cellular DNA during the S-phase, which requires
the viral E1 and E2 proteins. E2 is a multifunctional
DNA-binding protein that specifically recognizes the
consensus motif (AACCG(N4)CGGTT) (Dell et al.
2003), which is repeated multiple times in the non-coding
regulatory region or long control region (LCR) of the viral
genome. The association of E2 with binding motifs within
this region is necessary for the recruitment of the E1
helicase, which in turn melts the origin of replication and
recruits cellular proteins required for replication, such as
replication protein A and DNA polymerase a primase
(Masterson et al. 1998; Conger et al. 1999; Han et al.
1999; Loo & Melendy 2004). E2 also functions as a
transcription factor and regulates the expression of the E6
and E7 viral oncogenes by association with motifs within
the LCR that lie close to the early promoter.
In addition to its role in viral genome replication and
transcriptional regulation, E2 is required for the stable
maintenance of viral genomes by facilitating an intricate
segregation mechanism of viral genomes in dividing cells.
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human and animal papillomaviruses with subtle
differences between genera reported. Initial studies were
carried out using bovine papillomavirus type 1 (BPV-1).
The BPV-1 E2 protein associates with mitotic chromo-
somes throughout mitosis in a manner that requires
sequences within the N-terminal transactivation domain
of E2 (Skiadopoulos & McBride 1998; Ilves et al. 1999;
Bastien & McBride 2000; Abroi et al. 2004). From this, it
was hypothesized that the E2 protein from all papilloma-
virus types form a link between viral genomes, specifically
bound by the C-terminal DNA-binding domain of E2,
and mitotic chromosomes, bound by the N-terminal
transactivation domain of E2 via interaction with cellular
chromatin-associated protein(s). This is consistent with
the segregation mechanism of the other DNA viruses
described in this review, and has remained the common
theme for all HPVs tested with some subtle differences.
While BPV-1 E2 stably associates with chromosomes
throughout mitosis in numerous random foci, the E2
proteins from the alpha group (e.g. HPV-11, -16, -31 and
-57) have been shown to stably interact with mitotic
chromosomes only in early (prophase) and late (telophase)
mitosis, but not at the point of chromosomal separation
(anaphase) (Oliveira et al. 2006; Donaldson et al. 2007).
However, it was noted that the interaction of these E2
proteins with chromosomes throughout mitosis can be
observed if cells are pre-extracted prior to fixation (Oliveira
et al. 2006), suggesting that the interaction of alpha group
E2 proteins with mitotic chromosomes may occur but is
highly dynamic and unstable. The HPV-8 E2 protein
displays further differences in its mitotic localization pattern
in that it appears to associate with chromosomes only at
sites very close to the point of attachment of the mitotic
spindle. This is potentially in agreement with a study by
Van Tine et al. (2004) which showed that plasmids
containing E2-binding sites are localized in foci adjacent
to the spindle attachment site in an HPV-11 E2-dependent
manner, although further studies from the same group
have suggested that the HPV-11 E2 protein itself associates
with the spindles during mitosis (Van Tine et al. 2004;
Dao et al. 2006). However, the biological significance of
this remains unclear.
The search for the specific mechanism by which E2
tethers viral genomes to mitotic chromosomes has been
long standing, and the cellular proteins that E2 targets to
facilitate segregation of genomes remain unclear. It has
been reported that the bromodomain family member Brd4
is required for the attachment of HPV-31, HPV-16 and
BPV-1 E2 to mitotic DNA (You et al. 2004; Baxter et al.
2005; Abbate et al. 2006). In support of this, Brd4 and
BPV-1 E2 colocalize at punctuate foci on mitotic
chromosomes and overexpression of the C-terminal
domain (Brd4–CTD) or a small peptide shown to block
the interaction between E2 and Brd4 prevents the
association of E2 with host cell chromosomes and
enhances genome loss in BPV-1-transformed cells
(McPhillips et al. 2005; You et al. 2005; Abbate et al.
2006). While these data suggest a role for Brd4 in the
tethering of E2 to host cell chromosomes, it has also been
demonstrated that Brd4 associates with E2 to facilitate
E2-dependent transcriptional regulation (Ilves et al. 2006;
McPhillips et al. 2006; Schweiger et al. 2006; Senechal
et al. 2007; Wu & Chiang 2007), and that Brd4 is notProc. R. Soc. B (2009)required for the maintenance of all papillomavirus types
(McPhillips et al. 2006). In support of this, mutant E2
proteins that fail to associate with Brd4 and do not support
stable genome maintenance are unable to activate
transcription (Baxter et al. 2005; Abbate et al. 2006;
Ilves et al. 2006). This suggests that inhibition of Brd4
association is unlikely to only affect chromosome attach-
ment, but will also alter other important functions of E2
required for the replication and maintenance of viral
genomes. Furthermore, depletion of Brd4 using RNA
interference has no effect on the association of BPV-1 and
HPV-11 E2 proteins with mitotic chromosomes (Parish
et al. 2006a). Put together, these data certainly suggest a
role for Brd4 in the segregation of at least some
papillomavirus types but its necessity in this process
remains unresolved at present.
Other quests to isolate E2-associated cellular proteins
have isolated new candidates that are involved in the
segregation of papillomavirus genomes during mitosis. An
interaction between HPV-16 E2 and the topoisomerase
II-binding protein (TopBP1) has been described and shown
toenhance the transcriptional and replication activities of E2
(Boner et al. 2002). More recently, TopBP1 has been
hypothesized to be involved in viral genome segregation and
shown to regulate the association of E2 with chromatin. E2
and TopBP1 colocalize during latemitosis and it is suggested
that TopBP1 may be targeted by HPV-16 E2 to facilitate
mitotic tethering (Donaldson et al. 2007).
Using a yeast two-hybrid system to screen a yeast
cDNA library, an interaction between BPV-1 E2 and the
DEAH family DNA helicase chromosome loss 1 (Chl1)
was isolated (Parish et al. 2006a). Chl1 is required for the
efficient segregation of chromosomes (Gerring et al. 1990)
and studies on the human homologue, Chl-related 1
(ChlR1), have demonstrated a role in sister chromatid
cohesion (Parish et al. 2006b; Inoue et al. 2007). The E2
proteins from BPV-1 and HPV types 11 and 16 have been
shown to interact with ChlR1, demonstrating conserva-
tion of this interaction between genera. A mutant of BPV-
1 E2 (W130R) has been isolated that no longer associates
with ChlR1 but retains Brd4 binding, transcriptional
activation and E2-dependent viral replication functions
(Parish et al. 2006a). Although viral genomes that encode
E2 W130R are able to transiently replicate in mouse
fibroblasts, these genomes are not stably maintained,
indicating that ChlR1 interaction is required for the
maintenance of genomes over time and questions the
necessity for Brd4 interaction in the tethering of PV
genomes. This was confirmed by depletion of ChlR1,
which disrupts the association of E2 with mitotic
chromosomes. However, association is unaffected by the
depletion of Brd4. Interestingly, E2 and ChlR1 do not
colocalize during mitosis (Parish et al. 2006a), but a
robust interaction is observed during the S-phase
(A. Saade & J. L. Parish 2008, unpublished data)
indicating that ChlR1 is required for the loading of E2
and viral genomes onto chromatin during the S-phase,
possibly during cohesion establishment, and not for the
direct tethering of genomes to chromosomes during
mitosis. It remains to be seen whether ChlR1, Brd4 and/
or TopBP1 act in concert to facilitate the segregation of
viral genomes and whether these cellular proteins
contribute to a cellular pathway required for the accurate
segregation of chromosomes to daughter cells.
Table 1. Summary of the DNA viruses that actively segregate genomes during mitosis and the reported mechanisms by which
this is achieved.
virus
genome size
(base pairs)
viral protein required for
genome tethering
chromosomal association
pattern during mitosis
suggested associated cellular
protein(s) that facilitate segregation
EBV 165 000 EBNA-1 paired foci randomly associ-
ated with chromosomes
Histone H1 and EBP2
KSHV 140 000 LANA random speckles MeCP2, DEK, Brd2/4 histones H1,
H2A and H2B, NuMA
papillomavirus 8 000 E2 random speckles or foci near
spindle attachment region
Brd4, ChlR1 and TopBP1
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It is clear that many DNA tumour viruses have evolved
complex mechanisms to ensure genome persistence (as
summarized in table 1). There is much to be done to clearly
define the exact mechanism each virus employs. Whether
viruses that maintain genomes at low copy number have a
different mechanism of genome tethering from those
maintained at high copy number needs to be determined.
Viruses that maintain few episomal genomes per cell may
ensure that plasmids are not tethered to a single chromo-
some or multiple chromosomes that are segregated to one
daughter cell. Future studies that elucidate such a
mechanism will be fascinating. The importance of specific
cellular proteins that are targeted to facilitate genome
tethering must also be clearly defined. Nonetheless, the
current depth of understanding allows us to see the common
themes that have evolved to ensure the maintenance of
episomally maintained genomes of vastly different sizes from
diverse viral types. It is clear that all the viral types discussed
in this review encode a protein that functions to tether viral
genomes to host cell chromosomes during mitosis. This viral
protein is a DNA-binding protein that specifically associates
with consensus-binding sites within the viral genome,
meanwhile associating with mitotic chromosomes. The
association of these proteins with mitotic chromosomes
can either be direct or indirect, mediated by association with
host cell chromatin-bound proteins.
While the specific proteins each virus targets to mediate
genome tethering are diverse, some common themes exist.
For example, both KSHV LANA and papillomavirus E2
proteins have been shown to associate with bromodomain
proteins, and both LANA and EBV EBNA1 proteins
associate with components of the core histone. The
involvement of cohesin in the segregation of viral genomes
also seems to be consistent between different viral types.
Cohesin associates with KSHV genomes, and EBV
genomes are known to remain paired following replica-
tion. In addition, the tethering of papillomavirus genomes
requires the cohesin establishment factor ChlR1,
suggesting that this subset of viruses also target the
cohesion establishment pathway.
Numerous studies have shown that the disruption of
viral genome tethering during mitosis results in a loss of
viral genomes over time. This opens the door for the design
of novel antiviral therapeutics. In order for this to be
successful, several factors should be carefully considered.
Small molecules may need to be designed that affect only
the tethering and not the replication or transcriptional
functions of the viral protein(s) targeted. Such a small
molecule will ensure that viral oncoproteins are held under
strict transcriptional control and episomal genomesProc. R. Soc. B (2009)replicate normally. This will prevent any possibility of
forced integration, as has been suggested for papilloma-
viruses (Lusky & Botchan 1985; Lambert & Howley 1988;
Schiller et al. 1989; Taylor et al. 2003), although the
potential risk of integration owing to aberrant replication
needs to be further studied for a true link to be identified.
Nonetheless, the design of novel and highly specific
antiviral therapeutics that inhibit episomal genome tether-
ing resulting in genome loss through rounds of cell division
is an interesting concept and should be pursued.
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